The use of continuous glucose monitoring (CGM) and automated insulin delivery (AID) technologies can improve patient outcomes and overall quality of life while helping to reduce the long-term costs. However, current eligibility criteria imposed by many major commercial insurers limit access to these technologies among a large portion of the diabetes population. This narrative review and commentary highlights the evidence supporting the use of CGM and AID in the various diabetes populations, discuss the current eligibility criteria that make these technologies inaccessible to individuals who would benefit, and present recommendations for modifying these criteria.
